Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002022 · ClinicalTrials.gov registry record · NA

Treatment Program for Anemia in AIDS Patients

A NA study of HIV Infections and Cytopenias, sponsored by R W Johnson Pharmaceutical Research Institute.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002022: Completed NA study of HIV Infections and Cytopenias, sponsored by R W Johnson Pharmaceutical Research Institute.

NCT00002022 is a NA study of HIV Infections and Cytopenias that has completed, run by R W Johnson Pharmaceutical Research Institute. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002022, a NA study of HIV Infections and Cytopenias, has completed, sponsored by R W Johnson Pharmaceutical Research Institute.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Conditions Studied

HIV Infections Cytopenias

Interventions

  • DRUG Epoetin alfa

Study Locations (1)

New Jersey

  • R W Johnson Pharmaceutical Research Institute - Raritan

Trial Details

FieldValue
Phase NA
R W Johnson Pharmaceutical Research Institute

2 total trials

What the finished NCT00002022 record still lists

NCT00002022 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Epoetin alfa is the first listed.

NCT00002022 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002022 about?

NCT00002022 is a clinical study titled "Treatment Program for Anemia in AIDS Patients". The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

What is the current status of trial NCT00002022?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002022 study?

This clinical trial studies the following conditions: HIV Infections, Cytopenias.

What interventions are being tested in trial NCT00002022?

The interventions under investigation include: Epoetin alfa (DRUG).

Who is sponsoring clinical trial NCT00002022?

This trial is sponsored by R W Johnson Pharmaceutical Research Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002022 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002022, the US trial registry maintained by the National Library of Medicine. NCT00002022 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.